Literature DB >> 21488807

Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients--an observational, cross sectional study in four countries in Europe.

J C Virchow1, S Kay, P Demoly, J Mullol, W Canonica, V Higgins.   

Abstract

OBJECTIVE: It is hypothesised that the presence of ocular, in addition to nasal, symptoms among patients with allergic rhinitis (AR) results in poorer quality of life, reduced work productivity and increased resource utilisation. This study investigated the impact on quality of life, burden of illness and healthcare resources among 1640 AR patients.
METHODS: Data were drawn from an observational cross-sectional study of consulting patients undertaken in May/June 2008 in four European countries. Doctors provided records for the next four to five patients presenting with AR who filled out a self-completion survey which included the Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI:AS), the Mini Rhinoconjunctivitis Quality of Life Questionnaire (RQOLQ) and the Pittsburgh Sleep Quality Index (PSQI). Propensity scoring allied to regression-type analysis was used to assess the extra burden associated with ocular symptoms utilising two comparison groups (patients with nasal-only symptoms versus those with nasal and ocular symptoms). The analysis controlled for differences between the groups on confounding variables age, gender, smoking status and co-morbidities. The analysis was conducted twice, once controlling for differences between the groups in nasal severity and once without, recognising that it is not clear whether or not increased nasal severity symptoms are naturally associated with ocular symptoms. The severity of ocular symptoms as opposed to their presence alone was also assessed on outcome measures using regression type methods.
RESULTS: A total of 1009 patient records met the inclusion criteria, of whom 69% presented with both ocular and nasal symptoms. The results show that the presence of ocular symptoms reduces quality of life, reduces work productivity and increases resource utilisation irrespective of whether differences in severity of nasal symptoms are accounted for between the comparison groups. Patients with nasal and ocular symptoms require more healthcare consultations. All work-related domains were statistically different, with the presence of ocular symptoms associated with greater impact on work hours missed and impairment while working. For each of the above this was the case regardless of whether or not adjustment was made for nasal severity (both p < 0.05). Patients with nasal and ocular symptoms also record an additional half a day more time off work in the last 3 months as a result of AR (nasal severity unadjusted or adjusted, both p < 0.05). Clinically meaningful differences were found in overall quality of life score as represented by RQLQ, with a mean score increase of 0.6 (nasal severity unadjusted) and 0.5 (nasal severity adjusted) associated with the presence of ocular symptoms (both p < 0.05). With regard to sleep quality, the presence of ocular symptoms was associated with a mean increase in PSQI of 1 when no adjustment was made for nasal severity (p < 0.05). When nasal severity was adjusted for, no significant difference was observed. Similarly, for the number of prescribed medications, when no adjustment was made for nasal severity, patients with ocular symptoms were observed to receive a significantly higher number of AR drugs (+0.19, p < 0.05) whereas with nasal severity adjusted for the difference was +0.17 which was not significant. In addition, with the exception of the number of AR drugs prescribed, for all outcome variables, the severity of ocular symptoms, and not just their presence, had a detrimental impact on the outcome. LIMITATIONS: Since patients were recruited via the physician, the study aim was to represent the consulting population. In addition, it cannot be fully excluded that the likelihood for an individual patient to complete a questionnaire is influenced by differences in patient typology compared with those patients who chose not to complete. Given the geographical dispersion of the sample patients, it may be reasonable to assume possible differences in the intensity of the AR season based on latitude.
CONCLUSION: The added presence of ocular symptoms in AR patients suffering with nasal symptoms deteriorates patients' quality of life, leads to greater lost productivity and places higher burden on resource utilisation. Studies are therefore needed to test whether treatment options that address ocular in addition to nasal symptoms will improve quality of life and reduce both direct and indirect resource use associated with AR.

Entities:  

Mesh:

Year:  2011        PMID: 21488807     DOI: 10.3111/13696998.2011.576039

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  18 in total

1.  Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study).

Authors:  D J Costa; P Marteau; M Amouyal; L K Poulsen; E Hamelmann; M Cazaubiel; B Housez; S Leuillet; M Stavnsbjerg; P Molimard; S Courau; J Bousquet
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

2.  Evaluation of allergic sensitization in Lebanese patients with allergic conjunctivitis.

Authors:  Nicolas Arej; Carla Irani; Youssef Abdelmassih; Elise Slim; Joelle Antoun; Riad Bejjani; Alexandre Schakal; Naji Waked
Journal:  Int Ophthalmol       Date:  2017-08-22       Impact factor: 2.031

3.  Characteristics and predictors of allergic rhinitis undertreatment in primary care.

Authors:  F Spinozzi; N Murgia; S Baldacci; S Maio; A P Pala; C Casciari; M dell'Omo; G Viegi
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-17       Impact factor: 3.219

4.  Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials.

Authors:  Joseph B Ciolino; Eugene B McLaurin; Nicholas P Marsico; Stacey L Ackerman; Julia M Williams; Linda Villanueva; David A Hollander
Journal:  Clin Ophthalmol       Date:  2015-05-02

5.  Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.

Authors:  Gail Torkildsen; Abhijit Narvekar; Mark Bergmann
Journal:  Clin Ophthalmol       Date:  2015-09-14

6.  EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

Authors:  Moises A Calderon; Pascal Demoly; Roy Gerth van Wijk; Jean Bousquet; Aziz Sheikh; Anthony Frew; Glenis Scadding; Claus Bachert; Hans J Malling; Rudolph Valenta; Beatrice Bilo; Antonio Nieto; Cezmi Akdis; Jocelyne Just; Carmen Vidal; Eva M Varga; Emilio Alvarez-Cuesta; Barbara Bohle; Albrecht Bufe; Walter G Canonica; Victoria Cardona; Ronald Dahl; Alain Didier; Stephen R Durham; Peter Eng; Montserrat Fernandez-Rivas; Lars Jacobsen; Marek Jutel; Jörg Kleine-Tebbe; Ludger Klimek; Jan Lötvall; Carmen Moreno; Ralph Mosges; Antonella Muraro; Bodo Niggemann; Giovanni Pajno; Giovanni Passalacqua; Oliver Pfaar; Sabina Rak; Gianenrico Senna; Gabriela Senti; Erkka Valovirta; Marianne van Hage; Johannes C Virchow; Ulrich Wahn; Nikolaos Papadopoulos
Journal:  Clin Transl Allergy       Date:  2012-10-30       Impact factor: 5.871

7.  A survey of the burden of allergic rhinitis in Hungary from a specialist's perspective.

Authors:  Mária Szilasi; Gabriella Gálffy; Károly Fónay; Zsuzsa Márk; Zoltán Rónai; Zsuzsanna Szalai; Magdolna E Szilasi; Marianna Budai; Veronika Müller; Attila Somfay; Ildikó Horváth; Lilla Tamási
Journal:  Multidiscip Respir Med       Date:  2012-11-30

8.  Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey.

Authors:  Mark Small; James Piercy; Pascal Demoly; Helen Marsden
Journal:  Clin Transl Allergy       Date:  2013-10-09       Impact factor: 5.871

9.  Hydrocortisone concentration influences time to clinically significant healing of acute inflammation of the ocular surface and adnexa - results from a double-blind randomized controlled trial.

Authors:  Nikolay Sergiyenko; Ludmila Sukhina; Pavel Bezdetko; Yuriy Kovalenko; Nikolai Nikitin; Matthias Merzbacher; Dorothea Gross; Ralf Kohnen
Journal:  BMC Ophthalmol       Date:  2014-05-10       Impact factor: 2.209

10.  Hymenoptera venom allergy: work disability and occupational impact of venom immunotherapy.

Authors:  Giulia Paolocci; Ilenia Folletti; Kjell Torén; Giacomo Muzi; Nicola Murgia
Journal:  BMJ Open       Date:  2014-08-06       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.